EM2001F "Biosimilars in Oncology" (IM GR-012420)

To provide clinicians with both broad and oncology specific perspectives on biosimilars.

PDF icon Download Protocol

Target Audience

UT Southwestern faculty, fellows, residents and medical students, community physicians, nurse clinicians, physician assistants and nurses.

Learning Objectives

At the conclusion of this activity, the participant should be able to:

  • Explain the similarities and differences between biosimilars, reference biologics, and small molecule generics.
  • Compare available safety and efficacy data for available biosimilars and reference biologics and the potential impact of interchangeability, extrapolation of indications, and substitution on dose/response, adverse events, and clinical outcomes.
  • Summarize the key steps outlined by the FDA to demonstrate biosimilarity between a biosimilar and its reference biologic product.
Course summary
Available credit: 
  • 1.00 AMA
Course opens: 
Course expires: 

Photo: Nisha Unni, M.D.Nisha Unni, M.D.
Assistant Professor, Department of Internal Medicine
Division of Hematology and Oncology

Available Credit

  • 1.00 AMA


Please login or create an account to take this course.

Required Hardware/software

Activities should be run with recent versions of common browsers, including Internet Explorer, Firefox and Google Chrome